Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing reversal of HIV latency with combination therapy (pyrimethamine, lenalidomide, panobinostat)
2024-511192-15-00Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pyrimethamine, lenalidomide and panobinostat in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Erasmus MC. Primary endpoints: Fold change in cell-associated HIV-RNA at 6 and 24 hours and Safety and adverse events related to investigational drugs. Started May 2024; status: completed.
02
Drugs
pyrimethaminelenalidomidepanobinostat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-511192-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511192-15-00.